Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $157.57, for a total value of $2,363,550.00. Following the completion of the transaction, the director now owns 1,981,931 shares in the company, valued at approximately $312,292,867.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, May 15th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $127.32, for a total value of $1,909,800.00.
• On Wednesday, May 8th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $121.68, for a total value of $1,825,200.00.
• On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00.
• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00.

Moderna Price Performance

MRNA traded up $2.60 on Friday, reaching $166.61. 5,052,591 shares of the company’s stock were exchanged, compared to its average volume of 4,528,591. The stock’s fifty day moving average price is $115.62 and its 200-day moving average price is $100.39. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The stock has a market cap of $63.85 billion, a PE ratio of -10.63 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same period last year, the business earned $0.19 EPS. The company’s revenue was down 91.0% on a year-over-year basis. Sell-side analysts expect that Moderna, Inc. will post -7.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Evercore ISI assumed coverage on Moderna in a research report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price target on the stock. William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Canaccord Genuity Group boosted their price objective on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. UBS Group boosted their price objective on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, Oppenheimer boosted their price objective on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $126.46.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Moderna in the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares during the period. Cedar Wealth Management LLC boosted its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the period. Westside Investment Management Inc. acquired a new stake in Moderna in the first quarter valued at $32,000. Finally, Rise Advisors LLC raised its holdings in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.